4Egsmose C, Lund B, Borg G, et al. Patient swith rheumatoid arthritis benefit from early 2nd line therapy: 5-year follow up d a prospective double blind placebo contTolled study. JRheumatol, 1995, 22(12) :2208 - 2213.
5Paimela L, GrlpengeTg M, Kurki P, et al.Anfikeratin antibodies: diagnosfic and prognostic markers for early rheumatoid arthritis.Ann Rheum Dis, 1992, 51(6) :743 - 746.
6Despres N, Boire G, Lopez-Longo FJ, et al.The Sa system: a novel antigen-antlbody system specific for rheumatoM arthritis. J Rheumatol, 1994, 21 (6) : 1027- 1033.
7Vincent C, Simon M, Sebbag M, et 8.1. Immunoblotting detection of autoanfibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. J Rheumatol, 1998,25(5) :838- 846.
8Menard HA, Lapointe E, Rochdi M, et al.Insights into rheumatoid arthritis derived from a Sa immune system. Arthritis Res, 2000, 2(6) :429 - 432.
9ScheUekens GA, Visser H, de Jong BAW, et al. The diagnostic properties of rheumatoid arthritis recognizing a cyclic eitruUinated peptide. Arthritis Rheum, 2000, 43 ( 1 ) : 155- 163.
10Barland P, Lipstein E. Sdeetion and use of laboratory tests in rheumatic diseases. Am J Med, 1996, 100 (Suppl 2A) : 165 - 325.
